Amnio Bio is a biotech company developing regenerative therapies for stroke recovery through innovative scientific research. We are developing the world’s first regenerative stroke therapy using Human Amniotic Epithelial Cells (hAECs)—a breakthrough approach designed to support the body’s natural healing process after stroke.
Backed by more than 20 years of research, our team is committed to translating scientific discovery into innovative therapies that have the potential to improve recovery and restore quality of life for millions of patients worldwide.
To transform stroke recovery by delivering safe, effective regenerative therapies that improve patient outcomes and restore hope.
Stroke is a major cause of death and long‑term disability worldwide. Treatment for ischaemic stroke is limited to a 4.5‑hour window after a CT scan confirms the injury, yet many people arrive too late, unaware that irreversible damage has already occurred. Even when treated in time, current therapies focus on restoring blood flow, not repairing damaged brain tissue.
Amnio Bio was founded to address this unmet medical need by developing regenerative therapies that promote healing beyond the initial stroke event.
